More than 200 CF advocates from 47 states held nearly 400 meetings with members of Congress and their staff, and more than 850 advocates from across the country called their members of Congress as part of the CF Foundation's first March on the Hill online Day of Action.
March 19, 2018
|
3 min read
Phase 2 clinical trial results were announced today for a potential next-generation modulator to treat people with two copies of the most common cystic fibrosis mutation, F508del.
March 1, 2018
|
2 min read
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
Feb. 12, 2018
|
4 min read
The Cystic Fibrosis Foundation joined 28 patient and consumer organizations in responding to new Centers for Medicare and Medicaid Services (CMS) guidance issued by the administration that undermines patient protections granted by the Affordable Care Act.
Feb. 10, 2018
|
3 min read
Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
Jan. 31, 2018
|
4 min read
The drug company Corbus Pharmaceuticals will start its next Phase 2 clinical trial to test a potential inflammation-targeting drug in people with cystic fibrosis in the first quarter of 2018.
Jan. 30, 2018
|
3 min read